The MDR project (HIV multidrug resistance pathways in the EuResist Integrated DataBase) aims at estimating the prevalence and trend over time of MDR (multidrug resistance) in HIV patients, using descriptive statistics, retaining high value because of the large sample size and wide representativeness of the EIDB.
In addition, the project aims at identifying factors associated with development of MDR and deriving successful treatment strategies in MDR patients, based on GSS of possible rescue therapies: these challenging and ambitious tasks will benefit from machine learning approaches and the use of probabilistic models, under the responsibility of a multidisciplinary team with excellent specific and cross-talk capability, well-established through decennial cooperation within the EuResist consortium.
Publications
Rossetti B, Fabbiani M, Di Carlo D, Incardona F, Abecasis A, Gomes P, Geretti AM, Seguin-Devaux C, Garcia F, Kaiser R, Modica S, Shallvari A, Sönnerborg A, Zazzi M; EuResist Network, INTEGRATE study group
HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13262. Epub ahead of print. PMID: 35199909.
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study
Rossetti B, Fabbiani M, Di Carlo D, Incardona F, Abecasis A, Gomes P, Geretti AM, Seguin-Devaux C, Garcia F, Kaiser R, Modica S, Shallvari A, Sönnerborg A, Zazzi M; EuResist Network, INTEGRATE study group
J Antimicrob Chemother. 2021 Aug 12;76(9):2394-2399. doi: 10.1093/jac/dkab200. PMID: 34212176.
Integrating EuResist database with integrase resistance data for optimized antiretroviral treatment (the INTEGRATE project)
Maurizio Zazzi, Ana Abecasis, Marina Bobkova, Carole Devaux, Iuri Fanti, Francesca Incardona, Rolf Kaiser, Gaetano Marrone, Roger Paredes, Stefano Rusconi, Murat Sayan, Anders Sönnerborg and Andrea De Luca for the EuResist Network and the INTEGRATE study group. EACS 2017
HIV Type 1 Integrase Natural Polymorphisms in Viral Variants Circulating in FSU Countries. Lapovok, Laga, Kazennova, Bobkova, Curr HIV Res. 2017 Aug 15. [Epub ahead of print]
Genotypic susceptibility score of NRTI-backbone predicts time to virological failure of InSTIs-based regimens. A. Borghetti, A. Ciccullo, F. Lombardi, G. Baldin, S. Belmonti, M. Prosperi, F. Incardona, E. Heger, V. Borghi, A. Sönnerborg, M. Zazzi, A. De Luca, S. Di Giambenedetto. CROI 2019
Saladini, Francesco et al. “Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations.”
Antimicrobial agents and chemotherapy vol. 64,1 e01717-19. 20 Dec. 2019, doi:10.1128/AAC.01717-19 e 4-Class Resistance is rare in treatment experienced patients across Europe, M. Zazzi, A.M. Vandamme, B. Rossetti, M. Fabbiani, F. Incardona, K. Theys, A. Abecasis, C. Devaux, R. Kaiser, A. Sönnerborg, G. Pasculli, J. Vercauteren for the EuResist Network study group, CROI 2020
The Poster “Analysis of mutational history of multi-drug resistance with a mutagenetic tree model” will be presented at the next European Meeting on HIV & Hepatitis 2022 in Paris.
Project supported by a grant from ViiV Healthcare S.r.l.
- Start date: 19 March 2019
- End date:
- Grant amount: €
The study group includes clinicians, virologists and modelers with specific strong expertise in HIV drug resistance: Dr. A. Sönnerborg (KI), Dr. M. Zazzi (UNISI), Dr. R. Kaiser (UNIKOELN), : Dr. A.M. Vandamme (Rega Institute)
Project supported by a grant from ViiV Healthcare S.r.l.